Skip NavigationSkip to Content
Return Return to Search Results

A comparison of 18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer

  1. Author:
    Fourquet, Aloÿse
    Rosenberg, Adrian
    Mena, Esther
    Shih, Joanna J
    Turkbey, Baris
    Blain, Maxime
    Bergvall, Ethan
    Lin, Frank I
    Adler,Stephen
    Lim, Ilhan
    Madan, Ravi A
    Karzai, Fatima
    Gulley, James L
    Dahut, William L
    Wood, Bradford J
    Chang, Richard
    Levy, Elliot
    Choyke, Peter L
    Lindenberg, Liza

  2. Author Address

    Molecular Imaging Branch, National Cancer Institute, NIH., Division of Cancer treatment and Diagnosis : Biometric Research Program, National Cancer Institute, NIH., Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Cancer Institute, NIH., Clinical Research Directorate, Frederick National Laboratory for Cancer Research., Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences., Genitourinary Malignancies Branch, National Cancer Institute, NIH., 1.Molecular Imaging Branch, National Cancer Institute, NIH 2 .F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, United States.,
    1. Year: 2021
    2. Date: Sep 02
    3. Epub Date: 2021 09 02
  2. Journal: Journal of Nuclear Medicine : official publication, Society of Nuclear Medicine
    1. 63
    2. 5
    3. Pages: 735-741
  4. Type of Article: Article
  1. Abstract:

    Introduction:18F-DCFPyL, 18F-NaF and 18F-FDG PET/CT were compared in a prospective cohort of men with metastatic prostate cancer (PCa). Materials and Methods: 67 men (Group 1) with documented metastatic PCa underwent 18F-DCFPyL and 18F-NaF PET/CT and a subgroup of 30 men (Group 2) underwent additional imaging with 18F-FDG PET/CT. The tracers were compared for their detection rates, imaging concordance, associations with Prostate Specific Antigen (PSA), treatment at the time of imaging and castration status. Results: Overall, 61 men had metastatic disease detected on one or more scans, while 6 men were negative. In Group 1, 18F-NaF detected significantly more metastatic lesions than 18F-DCFPyL (median of 3 lesions versus 2, P = 0.001) even after eliminating benign causes of 18F-NaF uptake. This difference was particularly clear for men receiving treatment (P = 0.005) or who were castrate resistant (P = 0.014). The median percentage of bone lesions that were concordant on 18F-DCFPyL and 18F-NaF was 50%. In Group 2, 18F-DCFPyL detected more lesions than 18F-FDG (median of 5 lesions versus 2, P = 0.0003), regardless of PSA level, castration status or treatment. The median percentage of lesions that were concordant on 18F-DCFPyL and 18F-FDG was 22.2%. This percentage was slightly higher for castrate-resistant than castrate-sensitive men (P = 0.048). Conclusion:18F-DCFPyL PET/CT is the most versatile of the three PET agents for metastatic PCa however, 18F-NaF detects more bone metastases. Imaging reveals substantial tumor heterogeneity with only 50% concordance between 18F-DCFPyL and 18F-NaF and 22% concordance for 18F-DCFPyL and 18F-FDG. This indicates considerable phenotypic differences among metastatic lesions. Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.2967/jnumed.121.262371
  3. PMID: 34475237
  4. View record in Web of Science®
  5. WOS: 000792496500017
  6. PII : jnumed.121.262371

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel